A Phase 2 interventional study of Imetelstat sodium in Myelodysplastic Syndromes and Acute Myeloid Leukemia, sponsored by GCP-Service International West GmbH. Completed at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by GCP-Service International West GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies in Myelodysplastic Syndromes with a site in France — 36 open to participants now, 54 under way, 13 of them phase 3. Myelodysplastic Syndromes · France.
Among the 198 studies in Myelodysplastic Syndromes with a site in France, this one is the 118th largest by enrollment of the 172 interventional ones that give a count, is one of 10 that started in 2023, is one of 53 in phase 2, and was the 170th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →36 of the 198 studies in Myelodysplastic Syndromes with a site in France are open now. Recruiting first, the newest first:
Takeda · Sites in France, United States, Argentina and 25 more countries
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+
Groupe Francophone des Myelodysplasies · Sites in France
Ages 18+
Groupe Francophone des Myelodysplasies · Sites in France
Ages 18+
GlaxoSmithKline · Sites in France, United States, Canada and 6 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 53 · Phase 2 83 · Phase 3 46 · Phase 4 2
First in 1993; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 93 across the 172 interventional studies, 137 across the 25 observational. Of the 117 that completed or were terminated, 46 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 198 have an industry lead sponsor. The 10 most frequent:
GCP-Service International West GmbH is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
GCP-Service International West GmbH has 2 studies filed under Myelodysplastic Syndromes — fewer than ten, so there is no comparison to draw.
14 of the studies in Myelodysplastic Syndromes with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04401748Phase 3AbbVieStudy Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | 2027-07 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT06465953Phase 3Institut de Recherches Internationales ServierIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation | 2027-11-01 |
| NCT06987058Ryvu Therapeutics SARVU120 Rollover Study | 2026-12 |
| NCT06782373Swedish Orphan BiovitrumA Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | 2026-12-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 198 studies in Myelodysplastic Syndromes with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, in terms of hematologic improvement, and safety of imetelstat in participants with high-risk (HR) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that is relapsed/refractory to hypomethylating agents (HMAs) treatment. Responding patients are eligible to continue treatment until loss of response/disease progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Malignancy treated with curative intent and with no known active disease present for 3 years before day 1 of Cycle 1 Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease Adequately treated cervical carcinoma in situ without evidence of disease
Participant is in custody by order of an authority or a court of law Participation in another interventional clinical study within the last 3 months prior to signing the form (ICF) or simultaneous participation in other interventional clinical studies Previous assignment to treatment during this study Close affiliation with the investigator (e.g., a close relative) or persons working at the study site Participant is an employee of the sponsor or involved Contract Research Organization (CRO) Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the Participant's safety
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Imetelstat sodium
Intravenous injection
Also known as: GRN163L
Overall Hematological Response Rate of Participants After Treatment With Imetelstat
The combined response assessment criteria for MDS and AML based on IWG (International Working Group) 2018 criteria (MDS) and the criteria of the European LeukemiaNet (AML) will be used to define responders. The response rate is calculated as number of responders divided by the number of all participants of the analysis set.
Time frame: Up to Week 17 (Visit 9; approximately 17 weeks after first dose).
Toxicity Measured by NCI CTCAE v5.0 (National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0)
Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. A treatment-emergent adverse event (TEAE) was defined as any adverse event arising or worsening after the first dose of study drug. The number of participants experiencing at least one TEAE was summarized in the Safety Evaluation Set.
Time frame: From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).
Treatment Duration (Days)
The number of days between the first and last doses of study treatment. Subjects who discontinued early have duration calculated to their final dose date.
Time frame: From Treatment Start (Cycle 1 Day 1) to End of Treatment (EOT). Duration varies by subject.
Treatment Compliance
Percentage of study-drug doses received relative to the number of doses planned per protocol. Computed as: Compliance (%) = (Actual doses received ÷ Planned doses) × 100. Missed or undocumented doses are counted as not received unless justified per protocol or Statistical Analysis Plan (SAP). Dose holds and reductions are included in compliance assessment.
Time frame: From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).
Cumulative Dose (mg)
Total amount of imetelstat (mg) received across all treatment administrations. Calculated as the sum of all administered doses documented in the dose-administration eCRF (electronic Case Report Form). Notes: Dose reductions, missed doses, and dose delays are captured in the calculation. Missing dose records default to "not administered" unless clarified.
Time frame: From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject)
| Milestone | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) |
|---|---|---|
| Started | 23 | 23 |
| Completed | 0 | 3 |
| Not completed | 23 | 20 |
| Withdrew: Death | 15 | 13 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Physician decision | 4 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Progressive disease | 1 | 2 |
| Withdrew: Treatment inefficiency | 0 | 1 |
| Withdrew: Per protocol decision | 1 | 0 |
| Withdrew: Ongoing in the extension phase at data cutoff | 0 | 1 |
The combined response assessment criteria for MDS and AML based on IWG (International Working Group) 2018 criteria (MDS) and the criteria of the European LeukemiaNet (AML) will be used to define responders. The response rate is calculated as number of responders divided by the number of all participants of the analysis set.
| Participants | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) |
|---|---|---|
| Overall Hematological Response Rate of Participants After Treatment With Imetelstat | 0 | 1 |
Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. A treatment-emergent adverse event (TEAE) was defined as any adverse event arising or worsening after the first dose of study drug. The number of participants experiencing at least one TEAE was summarized in the Safety Evaluation Set.
| participants | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) |
|---|---|---|
| Toxicity Measured by NCI CTCAE v5.0 (National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0) | 23 | 23 |
The number of days between the first and last doses of study treatment. Subjects who discontinued early have duration calculated to their final dose date.
| days | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) |
|---|---|---|
| Treatment Duration (Days) | 53.8 ± 27.6 | 76.8 ± 71.7 |
Percentage of study-drug doses received relative to the number of doses planned per protocol. Computed as: Compliance (%) = (Actual doses received ÷ Planned doses) × 100. Missed or undocumented doses are counted as not received unless justified per protocol or Statistical Analysis Plan (SAP). Dose holds and reductions are included in compliance assessment.
| percentage | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) |
|---|---|---|
| Treatment Compliance | 70 ± 20 | 60 ± 30 |
Total amount of imetelstat (mg) received across all treatment administrations. Calculated as the sum of all administered doses documented in the dose-administration eCRF (electronic Case Report Form). Notes: Dose reductions, missed doses, and dose delays are captured in the calculation. Missing dose records default to "not administered" unless clarified.
| Milligrams | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) |
|---|---|---|
| Cumulative Dose (mg) | 1502.32 ± 511.08 | 2564.65 ± 1290.84 |
Collected over Adverse events were collected from informed consent until 28 (±5) days, up tp 1 month, after the last dose. Serious Adverse Events (SAEs) suspected to be related to imetelstat were collected at any time after discontinuation and documented without time limit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Imetelstat Sodium (1 Treatment / Cycle) | 15/23 (65.2%) | 18/23 (78.3%) | 23/23 (100%) |
| Imetelstat Sodium (2 Treatments / Cycle) | 13/23 (56.5%) | 19/23 (82.6%) | 23/23 (100%) |
| Event | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) |
|---|---|---|
| Transformation to acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/23 | 2/23 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/23 | 4/23 |
| Disease progressionGeneral disorders | 3/23 | 2/23 |
| PneumoniaInfections and infestations | 3/23 | 0/23 |
| PyrexiaGeneral disorders | 0/23 | 2/23 |
| SepsisInfections and infestations | 1/23 | 2/23 |
| AnaemiaBlood and lymphatic system disorders | 0/23 | 1/23 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/23 | 1/23 |
| Cardiac arrestCardiac disorders | 0/23 | 1/23 |
| Cardio-respiratory arrestCardiac disorders | 0/23 | 1/23 |
| Event | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) |
|---|---|---|
| AstheniaGeneral disorders | 8/23 | 7/23 |
| DiarrhoeaGastrointestinal disorders | 5/23 | 6/23 |
| Coronavirus infectionInfections and infestations | 6/23 | 1/23 |
| ConstipationGastrointestinal disorders | 2/23 | 5/23 |
| NauseaGastrointestinal disorders | 1/23 | 5/23 |
| Oedema peripheralGeneral disorders | 2/23 | 5/23 |
| AnxietyPsychiatric disorders | 5/23 | 2/23 |
| LeukocytosisBlood and lymphatic system disorders | 4/23 | 3/23 |
| NeutropeniaBlood and lymphatic system disorders | 4/23 | 2/23 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/23 | 4/23 |
| Age, Continuous(years) | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) | Total |
|---|---|---|---|
| Mean | 77.5 ± 4.8 | 77.7 ± 6.2 | 77.6 ± 5.5 |
| Sex/Gender, Customized(Participants) | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) | Total |
|---|---|---|---|
| Male | 15 | 14 | 29 |
| Female | 8 | 9 | 17 |
| Race (NIH/OMB)(Participants) | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 9 | 6 | 15 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 14 | 16 | 30 |
| WHO (World Health Organization) 2016 Disease Classification (MDS vs AML)(Participants) | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) | Total |
|---|---|---|---|
| MDS (Myelodysplastic Syndromes) | 6 | 5 | 11 |
| AML (Acute Myeloid Leukemia) | 17 | 18 | 35 |
| IPSS-R Risk Category(Participants) | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) | Total |
|---|---|---|---|
| Intermediate Risk | 0 | 2 | 2 |
| High Risk | 1 | 0 | 1 |
| Very High Risk | 4 | 4 | 8 |
| Score not done for AML | 18 | 17 | 35 |
| Cytogenetic Risk (Karyotype)(Participants) | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) | Total |
|---|---|---|---|
| Good | 1 | 2 | 3 |
| Intermediate | 1 | 1 | 2 |
| Poor | 3 | 1 | 4 |
| Very poor | 0 | 2 | 2 |
| Score not done for AML | 18 | 17 | 35 |
| Prior Azacitidine (AZA) cycles(Participants) | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) | Total |
|---|---|---|---|
| 1-6 cycles | 7 | 5 | 12 |
| 7-12 cycles | 8 | 8 | 16 |
| 13-24 cycles | 3 | 7 | 10 |
| ≥25 cycles | 5 | 6 | 11 |
| Prior Venetoclax (VEN) cycles(participants) | Imetelstat Sodium (1 Treatment / Cycle) | Imetelstat Sodium (2 Treatments / Cycle) | Total |
|---|---|---|---|
| 1-6 cycles | 8 | 5 | 13 |
| 7-12 cycles | 3 | 2 | 5 |
| 13-24 cycles | 1 | 1 | 2 |
| ≥25 cycles | 1 | 1 | 2 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2023 to primary completion in Mar 2025, 21 months.
Results were first posted in May 2026, 1 year 1 month after primary completion.
Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 21 months is below that.
Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.
Completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Sep 2025, on Oct 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imetelstat
GCP-Service International West GmbH